Principles of dose finding studies in cancer: a comparison of trial designs-Reference-Cited by-同舟云学术

Principles of dose finding studies in cancer: a comparison of trial designs

Published:2013-01-09 Issue:5 Volume:71 Page:1107-1114
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Jaki Thomas,Clive Sally,Weir Christopher J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-012-2059-8/fulltext.html

Reference35 articles.

1. Joffe S, Miller FG (2006) Rethinking risk-benefit assessment for phase I clinical trials. J Clin Oncol 24:2987–2990

2. Carter SK (1973) Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute. In: Staquet MJ (ed) The design of clinical trials in cancer therapy. Futura Publishing Co, Mount Kisco, pp 242–289

3. Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45:925–937

4. O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46:33–48

5. O’Quigley J, Chevret S (1991) Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat Med 10:1647–1664

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimands in Oncology Early Clinical Development: Assessing the Impact of Intercurrent Events on the Dose-Toxicity Relationship;Statistics in Biopharmaceutical Research;2023-12-18

2. Early phase clinical trials in oncology: Realising the potential of seamless designs;European Journal of Cancer;2023-08

3. Performance of phase‐I dose finding designs with and without a run‐in intra‐patient dose escalation stage;Pharmaceutical Statistics;2022-10-25

4. Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models;CPT: Pharmacometrics & Systems Pharmacology;2022-08-05

5. Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial;Contemporary Clinical Trials Communications;2022-04